2. Signaling Pathways
  3. Neuronal Signaling
  4. Amyloid-β

Amyloid-β

β-amyloid peptide; Aβ; Abeta

Amyloid-β

Related Products

PDF 1.52 MB

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N12360R
    2,3-Dehydrosilybin A (Standard)
    		Inhibitor
    2,3-Dehydrosilybin A (Standard) is the analytical standard of 2,3-Dehydrosilybin A. This product is intended for research and analytical applications. 2,3-Dehydrosilybin A is a pro-longevity and anti-aggregation compound.
    2,3-Dehydrosilybin A (Standard)
  • HY-P10935
    Amilo-5MER
    		Inhibitor
    Amilo-5MER (5-MP) is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER is promising for research of autoimmune diseases and chronic inflammatory diseases.
    Amilo-5MER
  • HY-175755
    Ac-BIM-acid bromide
    		Inhibitor
    Ac-BIM-acid bromide is a derivative of Acridine. Ac-BIM-acid bromide significantly inhibits amyloid fibrillation. Ac-BIM-acid bromide modulates the structure of N-terminal region of Saccharomyces cerevisiae Stm1 protein (Stm1_N1-113) and the amyloid morphology of human Aβ42 protein, inhibiting theirs growth. Ac-BIM-acid bromide can be used for Alzheimer’s disease research.
    Ac-BIM-acid bromide
  • HY-N2922R
    β-Amyrin (Standard)
    β-Amyrin shows effectively counteract amyloid β (Aβ)-induced impairment of long-term potentiation (LTP). β-Amyrin is a promising candidate for Alzheimer's disease (AD) research. β-Amyrin exhibits anti-inflammatory effects, protective activity against pulmonary fibrosis, and notable antibacterial capabilities. β-Amyrin is an orally active natural triterpenoid compound.
    β-Amyrin (Standard)
  • HY-P10824
    RI-OR2-TAT
    		Inhibitor
    RI-OR2-TAT is a brain-penetrant inhibitor of β-Amyloid oligomerization, which is produced by adding the HIV protein transduction domain TAT to RI-OR2. RI-OR2-TAT binds to Aβ42 fibrils with a Kd value of 58-125 nM. RI-OR2-TAT reduces Aβ aggregation and plaque levels, reduces activation of microglia and oxidative damage, and increases the number of young neurons in the dentate gyrus.
    RI-OR2-TAT
  • HY-139740
    Aβ Fibrillization modulator 1
    		Inhibitor
    Aβ Fibrillization modulator 1 stabilizes Aβ monomers.
    Aβ Fibrillization modulator 1
  • HY-N12249
    7-Deoxy-trans-dihydronarciclasine
    		Inhibitor
    7-Deoxy-trans-dihydronarciclasine, an alkaloid, is a tobacco mosaic virus (TMV) inhibitor (IC50: 1.80 μM). 7-Deoxy-trans-dihydronarciclasine is an anti-neuroinflammatory agent. 7-Deoxy-trans-dihydronarciclasine decreases the Aβ and APP levels in the cerebral cortex of Tg2576 mice.
    7-Deoxy-trans-dihydronarciclasine
  • HY-163320
    AChE/Aβ-IN-5
    		Inhibitor
    AChE/Aβ-IN-5 (compound AV-2) is a bifunctional inhibitor that targets AChE and auto-induced Aβ (Amyloid-β) aggregation. AChE/Aβ-IN-5 can significantly improve scopolamine- and Aβ-induced cognitive impairment in mice.
    AChE/Aβ-IN-5
  • HY-169614
    2002-G12
    		Inhibitor
    2002-G12 (compound 5a) is an Aβ42 inhibitor that can reduce Aβ42 toxicity by 76%. 2002-G12 can be used in Alzheimer's research.
    2002-G12
  • HY-118243
    KMS88009
    		Inhibitor
    KMS88009 is a potent small molecule that directly interferes with the formation of amyloid-β oligomers, thereby preserving cognitive behavior when used preventively and reversing cognitive behavior decline when used therapeutically. Oral administration of KMS88009 around the onset of Alzheimer's disease symptoms significantly reduced the assembly of amyloid-β oligomers and improved cognitive behavior in the APP/PS1 double transgenic mouse model. This unique dual mode of action suggests that KMS88009 may be a powerful therapeutic candidate for the treatment of Alzheimer's disease. In an evaluation, the physicochemical properties, pharmacokinetics and toxicity of this anti-amyloidogenic small molecule KMS88009 were studied, as well as post-mortem analysis of APP/PS1 TG mice after behavioral testing.
    KMS88009
  • HY-170658
    AChE-IN-80
    		Inhibitor
    AChE-IN-80 (Compound 1) is an acetylcholinesterase (AChE) inhibitor. AChE-IN-80 can inhibit inflammation and the production of reactive oxygen species (ROS) in vitro- cultured neurons and microglia, trigger autophagy responses, and block the propagation of β-amyloid (Aβ) fibrils. AChE-IN-80 possesses antioxidant activity and neuroprotective effects and can be used in the study of Alzheimer's disease.
    AChE-IN-80
  • HY-P1895
    β-Amyloid (33-40)
    β-Amyloid (33-40) is a peptide consisting of amino acid of 33 to 40 of beta amyloid protein.
    β-Amyloid (33-40)
  • HY-B1588S
    Carbenoxolone-d4
    		Inhibitor
    Carbenoxolone-d4 is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop.Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself.
    Carbenoxolone-d<sub>4</sub>
  • HY-P4865
    β Amyloid (3-40)
    β Amyloid (3-40) is aAβ Fragment.
    β Amyloid (3-40)
  • HY-122080
    Memoquin
    		Inhibitor
    Memoquin is an anti-amyloid and anti-oxidant multi-target-directed ligand. Memoquin is an orally active inhibitor of BACE-1 and AChE with IC50 values of 108 and 1.55 nM, respectively. Memoquin is a cognitive enhancer that prevents the Aβ-induced neurotoxicity mediated by oxidative stress. Memoquin can be used for the research of Alzheimer’s disease (AD).
    Memoquin
  • HY-P10035
    β Amyloid(28-35) human
    β Amyloid(28-35) human is a β-amyloid peptide (Abeta), a lipid-induced amyloid core fragment. β Amyloid oligomers are neurotoxic, and β Amyloid(28-35) human can interact with neuronal membranes, regulate secondary structure and neurotoxicity, and cause Alzheimer's disease. β Amyloid(28-35) human has anisotropic effects on the acidic phospholipid DPH, resulting in enhanced internal fluidity of lipid membrane bilayers.
    β Amyloid(28-35) human
  • HY-174305
    Aβ42-IN-7
    		Inhibitor
    Aβ42-IN-7 (Compound CT-01) is a brain-penetrant and selective amyloid-β42 (Aβ42) inhibitor. Aβ42-IN-7 inhibits Aβ42’s assembly into neurotoxic soluble oligomers and extracellular fibrillary aggregates. Aβ42-IN-7 exerts neuroprotective effects by reducing amyloid-mediated neuronal toxicity. Aβ42-IN-7 can be used in research on Alzheimer’s disease (AD).
    Aβ42-IN-7
  • HY-168273
    Glutaminyl cyclases-IN-2
    		Inhibitor
    Glutaminyl cyclases-IN-2 (compound 27) is a potent inhibitor of glutaminyl cyclase, with the IC50 of 0.08 μM. Glutaminyl cyclases-IN-2 plays an important role in cancer research.
    Glutaminyl cyclases-IN-2
  • HY-103374A
    Phenserine tartrate
    		Inhibitor
    Phenserine tartrate ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine tartrate reduces β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ) formation. Phenserine tartrate improves cognitive performance and attenuates the progression of Alzheimer's disease.
    Phenserine tartrate
  • HY-P3781
    (Met(O)35)-Amyloid β-Protein (1-42)
    (Met(O)35)-Amyloid β-Protein (1-42) is the oxidation form of Met35 in Aβ42. (Met(O)35)-Amyloid β-Protein (1-42) can yield an oligomer size distribution characteristic of Aβ40. (Met(O)35)-Amyloid β-Protein (1-42) can be used in the research of Alzheimer’s disease (AD).
    (Met(O)35)-Amyloid β-Protein (1-42)
Cat. No. Product Name / Synonyms Application Reactivity